We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    taiga biotechnologies
Previous Study | Return to List | Next Study

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04709458
Recruitment Status : Not yet recruiting
First Posted : January 14, 2021
Last Update Posted : May 3, 2022
Information provided by (Responsible Party):
Taiga Biotechnologies, Inc.

Brief Summary:

This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF).

The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way.

This study has two goals. The first goal is to find out if transplant with TBX-2400 is safe. The second goal is to find out what effects TBX-2400 stem cells have on time to engraftment in adult subjects with AML or MF.

The study hypothesis is that TBX-2400 cells will shorten the time to immune reconstitution after transplant.

Condition or disease Intervention/treatment Phase
Myelofibrosis Acute Myelogenous Leukemia Biological: TBX-2400 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis
Estimated Study Start Date : September 1, 2022
Estimated Primary Completion Date : August 28, 2024
Estimated Study Completion Date : October 28, 2024

Arm Intervention/treatment
Experimental: TBX-2400 treatment
Single intravenous infusion of TBX-2400
Biological: TBX-2400
Hematopoietic stem cells transplantation

Primary Outcome Measures :
  1. Incidence of adverse events according to NCI-CTCAE Version 5.0 [ Time Frame: Two years ]
    Adverse events from subject reporting or other assessments

  2. Transplant engraftment [ Time Frame: 1 year ]
    Assessment of transplant engraftment will include absolute neutrophil count, untransfused platelet count and donor chimerism

Secondary Outcome Measures :
  1. Immune reconstitution as measured by CD3+ cell count [ Time Frame: Up to Day 360 ]
    Immune reconstitution as measured by CD3+ cell count > 300/μL

  2. Immunoglobulin (IgA) levels [ Time Frame: Up to Day 360 ]
  3. Immunoglobulin (IgM) levels [ Time Frame: Up to Day 360 ]
  4. T-cell Engraftment [ Time Frame: Up to Day 360 ]
    CD45 RA versus RO at 3, 6, 9 and 12 months

  5. Disease-free survival [ Time Frame: Two years ]
  6. Incidence of secondary graft failure [ Time Frame: Two years ]
  7. Transplant-Related Mortality (TRM) [ Time Frame: 100 Days ]
  8. Quality of life using the World Health Organisation Five Wellbeing Index [ Time Frame: Up to day 360 ]
    QoL assessed at 3, 6, 9 and 12 months (World Health Organization [WHO] Five Wellbeing Index).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. For crAML: AML with ≥5% blasts (either by morphology or by multi-parameter flow cytometry [MFC]) in a marrow aspirate obtained within 21 days of enrollment in the trial, and following the administration of at least two prior courses of chemotherapy;
  2. For MF: primary MF or MF that has progressed from a myeloproliferative disease. Dynamic International Prognostic Scoring System (DIPSS)-plus to be utilized to support the inclusion of MF subjects at screening;
  3. Subject undergoing allogeneic stem cell transplantation on the decision of transplanting physician;
  4. Signed informed consent of donor and recipient;
  5. Subjects of ≥ 18 years of age (no upper age limit);
  6. Donor agrees to donate bone marrow-derived or mobilized peripheral blood stem cells;
  7. Subjects with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2;
  8. Adequate pulmonary function with Diffusing Capacity for Carbon Monoxide (DLCO) > 50;
  9. Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception (e.g. sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner with combined use of condom and/or birth control pills) from screening until 6 months after TBX-2400 transplantation;
  10. Able to adhere to all trial treatments and procedures.

Exclusion Criteria:

  1. Previous stem cell transplantation;
  2. For MF: Blasts > 10% in a marrow aspirate obtained within 30 days of screening;
  3. Renal function: serum creatinine > 1.5 x Upper Limit of Normal (ULN);
  4. Hepatic function: impaired synthetic function as indicated by a serum fibrinogen below the normal limit. Aspartate transaminase/alanine transaminase (AST/ALT) > 3.0 x ULN. Bilirubin, > 1.5 x ULN;
  5. Cardiac function: ejection fraction < 45% as determined by echocardiography;
  6. Prior malignancy active within previous three years - except for locally curable cancers such as cutaneous basal or squamous cell cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, or carcinoma in situ of the prostate;
  7. Positive pregnancy test or breastfeeding for women of childbearing age;
  8. Serologic evidence of chronic Hepatitis B virus infection or Hepatitis C exposure;
  9. Known history of positive test for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS);
  10. Hypersensitivity to any trial medication (including the preparative regimen, TBX-2400 treatment and any prophylaxis or other medication planned);
  11. Presence of a serious or uncontrolled medical disorder that, in the opinion of the Investigator, may increase the risk associated with trial participation or trial drug administration, impair the ability of the participant to receive protocol therapy, or interfere with interpretation of trial results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04709458

Layout table for location contacts
Contact: Vivienne Margolis, B.Sc +972-4639634 vmargolis@taigabiotech.com
Contact: Yosef Refaeli, Ph.D +1-720-859-3547 refaeli@taigabiotech.com

Layout table for location information
University Hospital Centre Zagreb
Zagreb, Croatia, 10000
Contact: Nadira Durakovic, MD, PhD    +385-989611829    nadira.durakovic@mef.hr   
Principal Investigator: Nadira Durakovic, MD, PhD         
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy, 00168
Contact: Simona Sica, MD    TBA    Simona.sica@unicatt.it   
Principal Investigator: Simona Sica, MD         
Sponsors and Collaborators
Taiga Biotechnologies, Inc.
Layout table for investigator information
Principal Investigator: Andrea Bacigalupo, MD Unit for Hematology and BMT, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Layout table for additonal information
Responsible Party: Taiga Biotechnologies, Inc.
ClinicalTrials.gov Identifier: NCT04709458    
Other Study ID Numbers: TBX-2400-001
First Posted: January 14, 2021    Key Record Dates
Last Update Posted: May 3, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Taiga Biotechnologies, Inc.:
Allogeneic stem cell transplant
Acute Myelogenous Leukemia
Myeloproliferative disorders
Primary myelofibrosis
Bone Marrow Cancer
Bone Marrow Transplant
Acute Myeloid Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Primary Myelofibrosis
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases